Oppenheimer & Co. Inc. lifted its stake in Danaher Corporation (NYSE:DHR - Free Report) by 9.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 25,096 shares of the conglomerate's stock after purchasing an additional 2,122 shares during the period. Oppenheimer & Co. Inc.'s holdings in Danaher were worth $5,145,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. LaFleur & Godfrey LLC raised its holdings in shares of Danaher by 1.5% in the 4th quarter. LaFleur & Godfrey LLC now owns 29,855 shares of the conglomerate's stock valued at $6,853,000 after purchasing an additional 440 shares in the last quarter. Bank Pictet & Cie Europe AG raised its holdings in shares of Danaher by 22.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 192,731 shares of the conglomerate's stock valued at $44,241,000 after purchasing an additional 35,730 shares in the last quarter. MONECO Advisors LLC raised its stake in Danaher by 13.5% in the fourth quarter. MONECO Advisors LLC now owns 1,502 shares of the conglomerate's stock valued at $345,000 after buying an additional 179 shares in the last quarter. IFP Advisors Inc raised its stake in Danaher by 2.9% in the fourth quarter. IFP Advisors Inc now owns 6,951 shares of the conglomerate's stock valued at $1,595,000 after buying an additional 197 shares in the last quarter. Finally, Edge Capital Group LLC raised its stake in Danaher by 4.1% in the fourth quarter. Edge Capital Group LLC now owns 3,707 shares of the conglomerate's stock valued at $851,000 after buying an additional 147 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on DHR shares. The Goldman Sachs Group cut their target price on Danaher from $260.00 to $240.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 23rd. Barclays raised their price objective on shares of Danaher from $215.00 to $225.00 and gave the stock an "overweight" rating in a report on Tuesday. JPMorgan Chase & Co. cut their price objective on shares of Danaher from $280.00 to $260.00 and set an "overweight" rating on the stock in a report on Tuesday, April 22nd. Argus cut their price target on shares of Danaher from $260.00 to $240.00 in a research note on Wednesday, April 23rd. Finally, Evercore ISI cut their price target on shares of Danaher from $240.00 to $230.00 and set an "outperform" rating on the stock in a research note on Tuesday, April 22nd. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $248.61.
Check Out Our Latest Stock Report on Danaher
Danaher Stock Performance
Shares of DHR opened at $197.51 on Wednesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43. The stock has a market capitalization of $141.35 billion, a P/E ratio of 38.35, a P/E/G ratio of 2.76 and a beta of 0.77. The company's fifty day moving average is $194.11 and its two-hundred day moving average is $209.06. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $281.70.
Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. Danaher had a net margin of 15.81% and a return on equity of 10.80%. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.58 billion. On average, sell-side analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.
Danaher Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.65%. Danaher's dividend payout ratio is presently 24.85%.
Insider Buying and Selling
In other news, Chairman Steven M. Rales sold 1,250,000 shares of the company's stock in a transaction on Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman now directly owns 3,105,808 shares of the company's stock, valued at $611,036,665.92. This represents a 28.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Christopher Paul Riley sold 15,805 shares of the company's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the transaction, the executive vice president now owns 15,179 shares in the company, valued at $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.20% of the stock is currently owned by corporate insiders.
Danaher Profile
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
